{"id":"valsartan-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Dizziness"},{"rate":"5-8","effect":"Fatigue"},{"rate":"2-4","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Cough"},{"rate":"3-5","effect":"Hypotension"},{"rate":"5-10","effect":"Hypokalemia (with HCTZ component)"},{"rate":"3-5","effect":"Hyperuricemia (with HCTZ component)"}]},"_chembl":{"chemblId":"CHEMBL1069","moleculeType":"Small molecule","molecularWeight":"435.53"},"_dailymed":{"setId":"d76a0419-05ee-437e-884c-65807aea9569","title":"DIOVAN HCT (VALSARTAN AND HYDROCHLOROTHIAZIDE) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing angiotensin II-mediated vasoconstriction and aldosterone release, thereby reducing blood pressure and cardiac workload. Hydrochlorothiazide, when combined, enhances antihypertensive efficacy by inhibiting sodium reabsorption in the distal convoluted tubule, promoting urinary sodium and water excretion. The combination provides complementary mechanisms for blood pressure control.","oneSentence":"Valsartan blocks angiotensin II receptors to relax blood vessels and lower blood pressure, while hydrochlorothiazide (when present) acts as a thiazide diuretic to reduce fluid volume.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:07.994Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction with left ventricular dysfunction"}]},"trialDetails":[{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT05609513","phase":"NA","title":"Integration of Hypertension Management in HIV Care in Uganda","status":"COMPLETED","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2023-02-06","conditions":"HIV/AIDS, Hypertension","enrollment":87421},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT03553810","phase":"PHASE2","title":"Role of ARNi in Ventricular Remodeling in Hypertensive LVH","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-04-12","conditions":"Hypertensive Heart Disease","enrollment":80},{"nctId":"NCT00546754","phase":"PHASE3","title":"BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05-01","conditions":"Hypertension","enrollment":808},{"nctId":"NCT06395194","phase":"PHASE3","title":"Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"1997-09-27","conditions":"Essential Hypertension","enrollment":15313},{"nctId":"NCT00171015","phase":"PHASE3","title":"VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-12","conditions":"Hypertension","enrollment":212},{"nctId":"NCT00171782","phase":"PHASE4","title":"Hypertension and Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-02","conditions":"HYPERTENSION","enrollment":76},{"nctId":"NCT05545059","phase":"PHASE3","title":"Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-09-24","conditions":"Resistant Hypertension","enrollment":138},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00523744","phase":"PHASE3","title":"Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-07","conditions":"Hypertension","enrollment":257},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00219102","phase":"PHASE3","title":"A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Hypertension, Diabetes","enrollment":336},{"nctId":"NCT01245608","phase":"PHASE3","title":"Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2011-10","conditions":"Cardiovascular Diseases","enrollment":2400},{"nctId":"NCT01271985","phase":"PHASE3","title":"Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2011-02","conditions":"Cardiovascular Diseases","enrollment":8410},{"nctId":"NCT00745953","phase":"PHASE4","title":"Regression of Fatty Heart by Valsartan Therapy","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-08","conditions":"Metabolic Syndrome, Lipotoxicity","enrollment":""},{"nctId":"NCT00168779","phase":"PHASE4","title":"Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09","conditions":"Hypertension","enrollment":1185},{"nctId":"NCT00250562","phase":"PHASE3","title":"A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Hypertension","enrollment":1171},{"nctId":"NCT00439738","phase":"PHASE4","title":"Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Hypertension","enrollment":412},{"nctId":"NCT02433119","phase":"PHASE4","title":"The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2015-03-16","conditions":"Hypertension","enrollment":238},{"nctId":"NCT00821574","phase":"PHASE4","title":"Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-07","conditions":"Hypertension, Dyslypidaemia","enrollment":144},{"nctId":"NCT00171574","phase":"PHASE4","title":"Antiproteinuric Effect of Valsartan and Lisinopril","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Hypertension, Diabetic Nephropathy","enrollment":124},{"nctId":"NCT00311740","phase":"PHASE3","title":"A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-03","conditions":"Hypertension","enrollment":582},{"nctId":"NCT00171132","phase":"PHASE4","title":"VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-08","conditions":"Hypertension","enrollment":64},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00170937","phase":"PHASE4","title":"A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION","enrollment":507},{"nctId":"NCT00360178","phase":"PHASE3","title":"Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-07","conditions":"Hypertension","enrollment":198},{"nctId":"NCT00327145","phase":"PHASE3","title":"A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-03","conditions":"Hypertension","enrollment":894},{"nctId":"NCT00304226","phase":"PHASE4","title":"Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-02","conditions":"Hypertension","enrollment":1288},{"nctId":"NCT00666536","phase":"PHASE4","title":"The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-03","conditions":"Hypertension","enrollment":728},{"nctId":"NCT01365481","phase":"PHASE3","title":"Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08","conditions":"Hypertension, Chronic Kidney Disease","enrollment":150},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT01256411","phase":"PHASE2","title":"A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11","conditions":"Essential Hypertension","enrollment":341},{"nctId":"NCT01819220","phase":"PHASE4","title":"Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-04","conditions":"Hypertension","enrollment":16},{"nctId":"NCT00386607","phase":"PHASE3","title":"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Hypertension","enrollment":601},{"nctId":"NCT01030458","phase":"PHASE4","title":"Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2010-09","conditions":"Blood Pressure","enrollment":183},{"nctId":"NCT01432106","phase":"PHASE1","title":"The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2011-02","conditions":"Hypertension, Metabolic Syndrome","enrollment":""},{"nctId":"NCT00239538","phase":"PHASE4","title":"SMOOTH - Blood Pressure Control in Diabetic/Obese Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-01","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":840},{"nctId":"NCT00240448","phase":"PHASE4","title":"A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Hypertension","enrollment":1109},{"nctId":"NCT01415505","phase":"PHASE3","title":"Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-08","conditions":"Hypertension","enrollment":812},{"nctId":"NCT01767259","phase":"NA","title":"Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2012-10","conditions":"Healthy Normotensive Participants","enrollment":24},{"nctId":"NCT01767298","phase":"NA","title":"Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2012-10","conditions":"Healthy Normotensive Participants","enrollment":24},{"nctId":"NCT00661895","phase":"PHASE4","title":"Black Education and Treatment of Hypertension (BEAT HTN)","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-08","conditions":"Hypertension","enrollment":99},{"nctId":"NCT00902304","phase":"PHASE4","title":"Valsartan Intensified Primary Care Reduction of Blood Pressure Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Hypertension","enrollment":2337},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00457483","phase":"PHASE4","title":"Nijmegen Antihypertensive Management Improvement Study","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2007-08","conditions":"Primary Hypertension","enrollment":120},{"nctId":"NCT00170989","phase":"PHASE3","title":"Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":"Hypertension","enrollment":2714},{"nctId":"NCT00171561","phase":"PHASE4","title":"Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-03","conditions":"Hypertension","enrollment":144},{"nctId":"NCT00273299","phase":"PHASE3","title":"Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-11","conditions":"Hypertension","enrollment":607},{"nctId":"NCT00327587","phase":"PHASE3","title":"8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-05","conditions":"Hypertension","enrollment":2279},{"nctId":"NCT00171535","phase":"PHASE3","title":"Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Hypertension","enrollment":130},{"nctId":"NCT00171444","phase":"PHASE4","title":"Comparison of Two Treatment Strategies in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-06","conditions":"Hypertension","enrollment":4445},{"nctId":"NCT00171600","phase":"PHASE4","title":"Antialbuminuric Effects of Valsartan and Lisinopril","status":"TERMINATED","sponsor":"Novartis","startDate":"2005-07","conditions":"Hypertension, Early Diabetic Nephropathy","enrollment":54},{"nctId":"NCT00241007","phase":"PHASE3","title":"A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-12","conditions":"Hypertension","enrollment":836},{"nctId":"NCT00338936","phase":"PHASE3","title":"Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-05","conditions":"Hypertension","enrollment":362},{"nctId":"NCT01425411","phase":"PHASE4","title":"Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Mustafa Kemal University","startDate":"2006-11","conditions":"Hypertension, Left Ventricular Hypertrophy","enrollment":38},{"nctId":"NCT01375322","phase":"PHASE4","title":"ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria","status":"COMPLETED","sponsor":"TSH Biopharm Corporation Limited","startDate":"2007-06","conditions":"Hypertension, Diabetes Mellitus, Type 2, Albuminuria","enrollment":226},{"nctId":"NCT00425997","phase":"PHASE4","title":"Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Hypertension","enrollment":480},{"nctId":"NCT00277472","phase":"PHASE4","title":"Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-11","conditions":"Hypertension","enrollment":300},{"nctId":"NCT00171054","phase":"PHASE4","title":"Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-09","conditions":"Hypertension","enrollment":125},{"nctId":"NCT00396656","phase":"PHASE3","title":"Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Hypertension","enrollment":30},{"nctId":"NCT00446563","phase":"PHASE3","title":"Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Hypertension; Hypertrophy, Left Ventricular","enrollment":90},{"nctId":"NCT00698646","phase":"PHASE4","title":"Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Hypertension","enrollment":384},{"nctId":"NCT00670787","phase":"PHASE3","title":"Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2008-06","conditions":"Hypertension","enrollment":207},{"nctId":"NCT00931710","phase":"PHASE4","title":"Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Stage 2 Systolic Hypertension","enrollment":488},{"nctId":"NCT00280540","phase":"PHASE4","title":"Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Hypertension","enrollment":648},{"nctId":"NCT00548067","phase":"PHASE3","title":"Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-09","conditions":"Hypertension","enrollment":111},{"nctId":"NCT00500604","phase":"PHASE4","title":"Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-07","conditions":"Hypertension","enrollment":1617},{"nctId":"NCT00424801","phase":"NA","title":"Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2007-01","conditions":"Microvascular Angina, Hypertension","enrollment":10},{"nctId":"NCT00687206","phase":"PHASE4","title":"Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage","status":"COMPLETED","sponsor":"Federico II University","startDate":"2008-03","conditions":"Hypertension, Ventricular Remodeling, Erectile Dysfunctions","enrollment":20},{"nctId":"NCT00426478","phase":"PHASE4","title":"Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Hypertension","enrollment":80},{"nctId":"NCT00400777","phase":"PHASE4","title":"Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":"Hypertension","enrollment":460},{"nctId":"NCT00487123","phase":"PHASE4","title":"Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months","status":"COMPLETED","sponsor":"Novartis","startDate":"","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[{"count":73,"reaction":"FATIGUE"},{"count":70,"reaction":"NAUSEA"},{"count":67,"reaction":"DIARRHOEA"},{"count":67,"reaction":"DIZZINESS"},{"count":62,"reaction":"DRUG INEFFECTIVE"},{"count":62,"reaction":"DYSPNOEA"},{"count":51,"reaction":"VOMITING"},{"count":47,"reaction":"HYPERTENSION"},{"count":43,"reaction":"ACUTE KIDNEY INJURY"},{"count":43,"reaction":"BLOOD PRESSURE INCREASED"}],"_approvalHistory":[{"date":"20210405","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA201087"},{"date":"20150601","type":"ORIG","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA201087"},{"date":"20210405","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA201087"},{"date":"20210405","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA201087"}],"publicationCount":102,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Valsartan+/- Hydrochlorothiazide","genericName":"Valsartan+/- Hydrochlorothiazide","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valsartan blocks angiotensin II receptors to relax blood vessels and lower blood pressure, while hydrochlorothiazide (when present) acts as a thiazide diuretic to reduce fluid volume. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction with left ventricular dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}